More on Gilead Science's (GILD) Q2: Revenues rise 15% Y/Y. Product sales rise 14% overall and...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

More on Gilead Science's (GILD) Q2: Revenues rise 15% Y/Y. Product sales rise 14% overall and 20% in the U.S. driven by growth in Complera/ Eviplera (+159% Y/Y). Stribild revenue was $99.394M during the period. Antiviral sales increase 15% to $2.31B. Antiviral sales growth by product: Atripla, +4%; Truvada, +3%; Viread, +16%. Cardiovascular product sales jump 19% Y/Y on a 26% increase in Letairis revenue. Shares +2.3% AH. (PR)